Infarmed, the Portuguese medicines regulator, decided to halt the distribution of a batch of the medication Salofalk due to a product registration anomaly. The competent authority prohibited the sale and dispensing of this specific batch.
However, the regulator made an appeal to patients not to interrupt their treatments without first consulting their doctor. This guidance aims to ensure continuity of healthcare and prevent patients from making hasty decisions regarding their medication.
Patients who have this batch of Salofalk should seek medical advice before making any changes to their therapy. This precautionary measure does not mean that the medication poses a direct risk to health, but rather that there is an administrative irregularity that prevents its normal commercialization.
